Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2010 1
2011 3
2012 2
2013 2
2014 8
2015 9
2016 7
2017 12
2018 25
2019 33
2020 10
2021 5
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33813414

103 results
Results by year
Filters applied: . Clear all
Page 1
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K. Paz-Ares L, et al. Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611. Ann Oncol. 2017. PMID: 28426106 Free PMC article. Clinical Trial.
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. Lin YT, et al. Int J Cancer. 2019 Jun 1;144(11):2887-2896. doi: 10.1002/ijc.32025. Epub 2019 Jan 5. Int J Cancer. 2019. PMID: 30485437 Free article.
103 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page